News

BiVictriX Therapeutics is an AIM listed emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer.

Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class.

BiVictriX’s Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company’s in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications.

The Company’s initial focus is on the generation of Bi-Cygni Antibody Drug Conjugates (ADCs), with future plans to expand the technology to other therapeutic modalities (Cell engagers and CAR-T).

Placing and Subscription

The Company has conditionally raised gross proceeds in aggregate of £2,133,415 million through the Placing of 9,268,579 Placing Shares and Subscription of 7,142,308 Subscription Shares at the Issue Price.

Upon completion, 16,410,887 new Ordinary Shares will be issued pursuant to the Fundraise at the Issue Price of 13 pence per new Ordinary Share.

For further information, click here.

Having produced the IPO admission document when BiVictriX floated on AIM in August 2021, their inaugural annual report in March 2022 and their subsequent annual report earlier this year, the Perivan shareholder communications team was delighted to work with SP Angel Corporate Finance who acted as Nominated Adviser and Broker and Panmure Gordon who acted as Joint Broker to BiVictriX at this further stage of their corporate journey, with the production of the documentation which was successfully completed and posted to qualifying shareholders on 20th July 2023.

Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.